

Alzheimer's, Parkinson's, diabetes, depression, cardiovascular disease: the scientific literature establishes links that clinical practice does not yet exploit.
We examine dozens of mouths every day. We see cavities, periodontitis, restorations to redo. But for twenty years, the scientific literature has told us we are also seeing something else, without knowing it: the first signs of systemic diseases no one else will detect in time.
Periodontitis is not only a local disease. It is a chronic inflammatory signal whose markers circulate throughout the body. Porphyromonas gingivalis, our most documented periodontal pathogen, has been identified in the brain tissue of patients with Alzheimer's. Its toxic proteases, the gingipains, correlate with tau pathology. This is no longer a hypothesis: it is a fact published in Science Advances.
In diabetes, the relationship is bidirectional and documented by hundreds of studies. One third of patients seen in a periodontal practice show an HbA1c in the diabetic or pre-diabetic range without knowing it. Chair-side screening, by a simple finger prick, could change the trajectory of millions of patients.
For cardiovascular disease, the excess risk is 19 to 22% in periodontal patients. For depression, the 2025 meta-analysis of 53 studies establishes an odds ratio of 1.30. And the oral-gut-brain axis opens unprecedented perspectives on Parkinson's.
The dentist may be the most regularly consulted healthcare professional in France. We see our patients every six months, sometimes more. We have access to the oral cavity, to saliva, to the oral microbiome. We hold a vantage point no one else occupies with this frequency and biological intimacy.
This volume explores what science already knows, what practice does not yet apply, and what technology now makes possible. Not to turn the dentist into a general practitioner, but to give them the tools of an informed sentinel.
P. gingivalis identified in the brains of AD patients. Gingipains correlated with tau. Salivary biomarkers Aβ42 and tau detectable. (Dominy et al., Science Advances, 2019)
Oral-gut-brain axis documented in 2025 (114 subjects). ×1.7 risk of neurodegenerative disease with periodontitis. Oral dysbiosis as a potential biomarker.
Bidirectional relationship established. 1/3 of periodontal patients with unrecognized pre-diabetes. Chair-side HbA1c screening validated (Clinical Oral Investigations, 2019).
CVD: OR 1.19-1.22, periodontal treatment reduces CRP. Depression: OR 1.30 (2025 meta-analysis, 53 studies, bidirectional relationship confirmed).
P. gingivalis crosses the blood-brain barrier. In mice, oral infection leads to brain colonization and increased production of Aβ1-42, a component of amyloid plaques. [1]
Gingipains (bacterial proteases) trigger an inflammatory cascade in brain tissue. Their levels correlate with tau protein and ubiquitin load. [1]
2025 study (114 subjects): the oral microbiome influences the gut microbiome through the daily swallowing of 1.5 L of saliva. Oral dysbiosis propagates and alters the gut-brain axis implicated in Parkinson's. [2]
Depressed patients show an odds ratio of 1.30 for periodontitis, 1.32 for cavities, and 1.26 for edentulism. The relationship is bidirectional: depression degrades hygiene and salivary immunity, while chronic pain and periodontal inflammation worsen depressive symptoms.
A systematic review of clinical trials shows that periodontal treatment reduces C-reactive protein (CRP) in 78% of cases, interleukin-6 in 100% of studies, and improves fibrinogen in 67% of cases. These markers are directly correlated with cardiovascular risk.
When a periodontal patient is referred for diabetes screening and pre-diabetes is detected, early intervention (lifestyle changes, glucose monitoring) prevents progression to type 2 diabetes. The cost of a chair-side HbA1c test is negligible compared to the cost of untreated diabetes over five years.
Artificial intelligence now allows periodontal data, medical history and biological markers to be cross-referenced to generate a personalized risk score. Yalha embeds this logic in its clinical flow: the practitioner receives a contextual alert, not a diagnostic instruction.

Being able to also analyze screenshots of optical impressions is a real asset, as it allows color to be integrated and further enriches the quality of the diagnosis.

The dental surgeon is probably the most regularly consulted healthcare professional in France. And yet, their role in the prevention of systemic diseases remains nearly nonexistent in official recommendations.
We now have enough scientific evidence to state that the oral cavity is a reliable marker of overall health. Periodontitis correlates with diabetes, cardiovascular disease, neurodegenerative disease and depression. Saliva contains biomarkers usable for the early detection of these conditions.
What is missing is not science. It is infrastructure. The clinical tools that allow the practitioner to collect, interpret and transmit these signals within the framework of their daily practice. Without disproportionate additional training, without extra administrative burden, without stepping outside their scope of competence.
Yalha is building this infrastructure. An ecosystem where periodontal data automatically generates systemic risk alerts, where the practitioner can refer the patient to their primary physician with a structured report, and where traceability protects everyone.
For thirty years, I have treated periodontitis. For twenty years, I have been a court-appointed expert at the Court of Appeal of Pau. These two roles have taught me the same thing: what we see in a mouth goes far beyond the boundaries of the oral cavity.
Periodontitis is a chronic inflammatory disease. Its mediators circulate throughout the body. Periodontopathogenic bacteria do not stay confined to gingival pockets: they enter the bloodstream with every brushing, every mastication, every scaling. The resulting chronic endotoxemia fuels a low-grade systemic inflammation whose effects on the brain, the heart and metabolism are now documented.
As a periodontist, I measure every day pocket depth, attachment level, bleeding index. These numbers are not only periodontal indicators. They are indirect markers of systemic risk. The literature says so. Our practice must integrate it.

The question is no longer whether periodontitis has systemic consequences. The question is why we are not yet systematically documenting it.
In the expert files I examine, the court increasingly asks whether the practitioner identified the risk factors, whether they documented them, whether they referred the patient. A severe periodontal patient who develops type 2 diabetes or a cardiovascular event within five years raises a traceability question our profession must anticipate.
Periodontal documentation can no longer be limited to charting. It must include the medical context, the risk factors identified, the referrals proposed. A periodontal score correlated with systemic risk, integrated into the patient record, is not a technological luxury. It is professional prudence.
The tool Yalha is developing goes in this direction. By cross-referencing periodontal data with medical history and generating risk alerts, it turns a routine examination into an act of systemic prevention. Without overloading the practitioner, without stepping outside their scope of competence.
21st-century medicine will be preventive and integrated, or it will not be. The periodontist, by the very nature of their practice, is on the front line of this transformation. It is time our tools reflected this reality.

At last, a system that frees us from time-consuming administrative constraints. Clinical reports, treatment plans, estimates, informed consents… everything is generated rigorously, with no risk of omission. An indispensable tool to save precious time while optimizing patient communication through the CheckMyTeeth application. We can finally focus fully on delivering care.